PAI
ELDN icon

Pittenger & Anderson Inc’s Eledon Pharmaceuticals ELDN Stock Holding History

Pittenger & Anderson Inc’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$138 Hold
35
– – ﹤0.01% 504
2026
Q1 		$108 Buy
+35
New +$82 ﹤0.01% 520

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Pittenger & Anderson Inc's ELDN Position: Q2 2026 in Review

Pittenger & Anderson Inc held its Eledon Pharmaceuticals (ELDN) position steady in Q2 2026 at 35 shares worth $138. The position accounts for ﹤0.01% of the portfolio, ranked #504.

Pittenger & Anderson Inc first reported a position in ELDN in Q1 2026 and has held it in 2 quarters since. 160 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Pittenger & Anderson Inc held 35 shares of Eledon Pharmaceuticals worth $138 as of Q2 2026.
  • Pittenger & Anderson Inc left its Eledon Pharmaceuticals share count unchanged in Q2 2026.
  • Eledon Pharmaceuticals made up ﹤0.01% of Pittenger & Anderson Inc's portfolio in Q2 2026, its #504 holding.
  • Pittenger & Anderson Inc first reported a position in Eledon Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 160 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Pittenger & Anderson Inc's 13F filing for Q2 2026, filed 27 Jul 2026.